EC approves Eisai advanced breast cancer drug
Eribulin mesylate was approved by the US Food and Drug Administration (FDA) on 15 November 2010, to treat patients with metastatic breast cancer who have received at least
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.